.png)
Do you know that....
DMD patients usually lose the ability to walk by age 12 and often die of respiratory failure or cardiac insufficiency around age 20
01
High Prevalence and Genetic Factors
Spinal Muscular Atrophy (SMA) is significantly more prevalent in the Gulf Cooperation Council (GCC) populations, with rates at least 50 times higher than in the US due to genetic factors like consanguinity. Duchenne Muscular Dystrophy (DMD), caused by a mutation on the X chromosome, primarily affects male children and leads to progressive muscle degeneration.
02
Challenges in Diagnosis and Progression
Traditional diagnostic methods for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD), such as muscle biopsies and high-field MRI scans, are limited by their financial burden, long time span, accuracy issues, and invasiveness. Low-field MRI combined with AI offers a more cost-efficient, faster, accurate, and non-invasive alternative, providing a comprehensive and reliable diagnosis while reducing patient discomfort and healthcare costs.
The price of the MRI scans ranges from $110 to $2,000 in the United States and $110 to $1,100 in the UAE
Turnaround time
Muscle biopsies require several weeks for processing and analysis, while high-field MRI scans depend on the availability of specialized radiologists to interpret the results, leading to delays.
Accuracy
Muscle biopsies' accuracy is limited to the sampled area and may miss early disease indicators present in other muscles. High-field MRI scans are accurate but require manual interpretation, which can introduce variability.
Invasiveness
Traditional diagnostic methods like muscle biopsies are limited in scope. It is also invasive and often painful, requiring recovery time.
03
Importance of Early Diagnosis and Advanced Tools
The severe complications of DMD, including cardiac and respiratory issues, underscore the importance of early diagnosis and treatment to slow disease progression.
Therefore, there is a critical need for innovative, non-invasive diagnostic tools and comprehensive care plans to address these challenges. Our project aims to fill this gap by providing state-of-the-art diagnostic solutions and personalized care strategies.
